Clinical trials
Completed Colitis, Ulcerative trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
817 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 3 |
| 2001 | 3 |
| 2002 | 7 |
| 2003 | 17 |
| 2004 | 11 |
| 2005 | 17 |
| 2006 | 24 |
| 2007 | 30 |
| 2008 | 26 |
| 2009 | 26 |
| 2010 | 24 |
| 2011 | 36 |
| 2012 | 45 |
| 2013 | 38 |
| 2014 | 48 |
| 2015 | 57 |
| 2016 | 57 |
| 2017 | 48 |
| 2018 | 50 |
| 2019 | 41 |
| 2020 | 44 |
| 2021 | 45 |
| 2022 | 37 |
| 2023 | 35 |
| 2024 | 34 |
| 2025 | 9 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 817 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Takeda | 33 |
| Pfizer | 22 |
| AbbVie | 20 |
| Ferring Pharmaceuticals | 16 |
| Bausch Health Americas, Inc. | 15 |
| Shire | 14 |
| Janssen Research & Development, LLC | 10 |
| Mayo Clinic | 10 |
| Second Affiliated Hospital of Wenzhou Medical University | 9 |
| Bristol-Myers Squibb | 8 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Colitis, Ulcerative | 817 |
| Crohn Disease | 294 |
| Inflammatory Bowel Diseases | 275 |
| Colitis | 26 |
| Arthritis, Rheumatoid | 22 |
| Arthritis, Psoriatic | 17 |
| Spondylitis, Ankylosing | 16 |
| Irritable Bowel Syndrome | 13 |
| Psoriasis | 12 |
| Ulcer | 12 |
Trials
Showing 76 to 100 of 817. Each trial links to its page on Pharma Observatory.
717 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.